Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Allergy Therapeutics shares key scientific findings from innovative research portfolio at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2023

9 June 2023 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that the Group will be sharing key scientific findings from across its research portfolio at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place from today until 11 June 2023 in Hamburg, Germany.

The EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 12,000 clinicians, researchers, and allied health professionals, dedicated to improving the health of people affected by allergic diseases.

Among its nine posters being presented, Allergy Therapeutics will share:

·      Further clinical and preclinical studies on biomarker strategies, patient responses and the mechanism of action of allergy immunotherapies. Part of the data is derived from the positive G309 exploratory field study which evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. These findings supported the design of the ongoing pivotal Phase III Grass MATA MPL G306 trial, which is on track to report interim topline safety & efficacy data in Q4 2023.

·      Further pre-clinical data characterising the mechanism of action of the Group's novel virus-like particle (VLP) based peanut allergy vaccine candidate ("VLP Peanut"), which is currently being investigated in the Phase I PROTECT trial with plans on track for data later in 2023.

·      Preclinical studies examining allergenic venom homology, an area in which the Group is currently commercially active.

Allergy Therapeutics will also be hosting a hybrid symposium, "SCIT; pioneering a new era", on Saturday 10 June, 14:30-15:30 CEST, chaired by Professor Dr. med. Ludger Klimek, Head of the Centre for Rhinology and Allergology, Wiesbaden, Germany. The symposium will consist of three presentations covering the topics of venom immunotherapy, biomarker strategies in allergy immunotherapy and an analysis of the VLP Peanut PROTECT study, further exploring how the trial's study design bridges the pre-clinical and clinical boundaries.

Results from the completed G309 exploratory field trial, investigating Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, have been accepted for upcoming publication in the official journal of the EAACI, Allergy. During the EAACI congress on Sunday 11 June at 15:00 - 15:30 CEST, Professor Mohamed Shamji, Reader in Immunology & Allergy at Imperial College London, will give an overview of this recently accepted publication titled "Short-course subcutaneous pre-seasonal treatment with a 13-grass pollen allergoid reduces allergy symptoms and relief medication use in allergic rhinitis: A randomised, double-blind, placebo-controlled adaptive trial". This session will be in Hall Y 7 on Level 2 during the SY 19 - Cutting Edge in Allergy, Asthma and Immunology session.

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, commented: "We are excited to be participating in this year's EAACI congress, joining like-minded scientists and industry professionals, united in one mission - to improve the lives of people living with allergies. With two innovative short-course allergy immunotherapies currently in the clinic, Allergy Therapeutics is delivering on its commitment to develop the next generation of allergy immunotherapies with the potential to transform patients' lives. The Phase III trial of our short-course grass pollen immunotherapy candidate, Grass MATA MPL, and the Phase I PROTECT trial of our peanut allergy vaccine candidate, VLP Peanut, are currently underway and we are looking forward to sharing further insights with the community on these potentially transformative allergy therapies."

The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website.

No new material price sensitive information is expected to be disclosed on Allergy Therapeutics at the EAACI Congress 2023. 

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.